全文获取类型
收费全文 | 7272篇 |
免费 | 589篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 120篇 |
儿科学 | 170篇 |
妇产科学 | 121篇 |
基础医学 | 879篇 |
口腔科学 | 104篇 |
临床医学 | 906篇 |
内科学 | 1569篇 |
皮肤病学 | 160篇 |
神经病学 | 444篇 |
特种医学 | 211篇 |
外科学 | 1019篇 |
综合类 | 47篇 |
一般理论 | 1篇 |
预防医学 | 588篇 |
眼科学 | 182篇 |
药学 | 711篇 |
中国医学 | 55篇 |
肿瘤学 | 594篇 |
出版年
2024年 | 13篇 |
2023年 | 96篇 |
2022年 | 240篇 |
2021年 | 400篇 |
2020年 | 223篇 |
2019年 | 280篇 |
2018年 | 297篇 |
2017年 | 199篇 |
2016年 | 212篇 |
2015年 | 229篇 |
2014年 | 287篇 |
2013年 | 359篇 |
2012年 | 499篇 |
2011年 | 500篇 |
2010年 | 247篇 |
2009年 | 245篇 |
2008年 | 378篇 |
2007年 | 405篇 |
2006年 | 353篇 |
2005年 | 354篇 |
2004年 | 287篇 |
2003年 | 291篇 |
2002年 | 252篇 |
2001年 | 185篇 |
2000年 | 168篇 |
1999年 | 148篇 |
1998年 | 66篇 |
1997年 | 58篇 |
1996年 | 46篇 |
1995年 | 24篇 |
1994年 | 27篇 |
1993年 | 15篇 |
1992年 | 56篇 |
1991年 | 53篇 |
1990年 | 78篇 |
1989年 | 49篇 |
1988年 | 33篇 |
1987年 | 32篇 |
1986年 | 32篇 |
1985年 | 29篇 |
1984年 | 30篇 |
1983年 | 16篇 |
1982年 | 9篇 |
1981年 | 9篇 |
1980年 | 6篇 |
1979年 | 7篇 |
1978年 | 9篇 |
1976年 | 5篇 |
1973年 | 8篇 |
1972年 | 6篇 |
排序方式: 共有7881条查询结果,搜索用时 15 毫秒
61.
Dawson Luke P. Dinh Diem T. Stub Dion Ahern Susannah Bloom Jason E. Duffy Stephen J. Lefkovits Jeffrey Brennan Angela Reid Christopher M. Oqueli Ernesto 《Quality of life research》2022,31(8):2375-2385
Quality of Life Research - During the COVID-19 pandemic, widespread public health measures were implemented to control community transmission. The association between these measures and... 相似文献
62.
63.
Neil K. Jairath Alan Dal Pra Randy Vince Robert T. Dess William C. Jackson Jeffrey J. Tosoian Sean M. McBride Shuang G. Zhao Alejandro Berlin Brandon A. Mahal Amar U. Kishan Robert B. Den Stephen J. Freedland Simpa S. Salami Samuel D. Kaffenberger Alan Pollack Phuoc Tran Rohit Mehra Daniel E. Spratt 《European urology》2021,79(3):374-383
ContextMolecular biomarkers aim to address the established limitations of clinicopathologic factors to accurately risk stratify patients with prostate cancer (PCa). Questions remain as to whether sufficient evidence supports adoption of these biomarkers for clinical use.ObjectiveTo perform a systematic review of the available evidence supporting the clinical utility of the Decipher genomic classifier (GC).Evidence acquisitionThe review was performed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines by searching PubMed and conference abstracts from January 2010 to June 2020. Evidence was then graded using the criteria of Simon et al (Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446–52) and American Urology Association (AUA) criteria.Evidence synthesisIn total, 42 studies and 30 407 patients were included. GC performance data were available for localized, postprostatectomy, nonmetastatic castration-resistant, and metastatic hormone-sensitive PCa as part of retrospective studies (n = 12 141), prospective registries (n = 17 053), and prospective and post hoc randomized trial analyses (n = 1213). In 32 studies (n = 12 600), the GC was independently prognostic for all study endpoints (adverse pathology, biochemical failure, metastasis, and cancer-specific and overall survival) on multivariable analysis and improved the discrimination over standard of care in 24 studies (n = 8543). GC use changed the management in active surveillance (number needed to test [NNT] = 9) and postprostatectomy (NNT = 1.5–4) settings in five studies (n = 4331). Evidence strength was levels 1 and 2 by the Simon criteria for all disease states other than high-risk PCa, and grades A and B by AUA criteria depending on disease state.ConclusionsConsistent data are now present from diverse levels of evidence, which when viewed together, have demonstrated clinical utility of the GC in PCa. The utility of the GC is strongest for intermediate-risk PCa and postprostatectomy decision-making.Patient summaryIn this paper, we review the evidence of the Decipher genomic classification tool for men with prostate cancer. We found consistent evidence that the test helps identify which cancers are more or less aggressive, which in turn aids in personalized treatment decision-making. 相似文献
64.
Lasers in Medical Science - Long-pulsed 1064-nm (LP1064) and 755-nm (LP755) lasers have been demonstrated as effective treatments for leg veins. However, few studies of these treatments on Asian... 相似文献
65.
66.
Hernia - The optimal approach for inguinal hernia repair in the obese remains elusive. Minimally invasive techniques show equivocal results compared to the open method. None of the current analyses... 相似文献
67.
68.
Alexander C. Castillo Kyle Kaltwasser Randal Morris Erick R. Sanchez Surjit Rai Nicholas Lombana Dat Tran Ludwik Branski Andrew Y. Zhang 《Hand (New York, N.Y.)》2021,16(1):67
Background: Skeletal muscle lacerations are a relatively common injury. Compared with nonrepaired lacerations, surgically repaired muscle lacerations regenerate faster, develop less scar tissue, have a higher return to baseline strength, and have lower incidence of hematomas. Despite the benefits of repair, the optimal repair technique is still unknown. The purpose of this study was to examine the biomechanical properties of common muscle repair techniques to determine the optimal repair. Methods: Forty-two fusiform porcine muscle specimens were dissected and used for this study. Three suture techniques were used for comparative analysis: Figure-eight, Mason Allen, and Perimeter. Each muscle was transected and then repaired using one of the 3 techniques. Fourteen muscle-tendon specimens were prepared for each group and tested for tensile failure using a material testing system. Biomechanical properties, including peak failure point and stiffness, were compared for differences between the suture groups by 1-way analysis of variance. The average time per repair technique was also recorded. Results: The Perimeter technique showed a statistically significant higher peak failure point than the Mason Allen technique (P = .03). Both the Figure-eight (P = .047) and Perimeter techniques (P < .001) were significantly stiffer than the Mason Allen technique. The repair time was comparable across all 3 techniques. Conclusions: The Figure-eight and Perimeter repairs were found to be similar in peak failure point and stiffness, whereas the Mason Allen technique showed significantly lower stiffness and peak failure point. The Figure-eight was the quickest repair to perform. The Figure-eight technique may be strongly considered for muscle laceration repairs due to its simplicity and efficiency. 相似文献
69.
Archives of Sexual Behavior - 相似文献
70.
Nguyen Minh Hai Nguyen Dang Dung Dinh Cong Pho Vu Tung Son Vu Ngoc Hoan Phan Tan Dan Bui Dang The Anh La Huong Giang Pham Ngoc Hung 《Vaccine》2021,39(7):1140-1147
BackgroundROTAVAC® is derived from human 116E rotavirus (RV) neonatal strain. In this study, we evaluated the immunogenicity, safety and reactogenicity of ROTAVAC® in Vietnam.MethodWe conducted a phase IV clinical trial in healthy infants aged 6–8 weeks using the complete regimen of ROTAVAC® with three doses. Serum anti-RV IgA was measured by enzyme-linked immunosorbent assay to assess the geometric mean concentration in infants who received the complete regimen of the vaccine.ResultsA total of 360 participants were enrolled in this clinical trial. The mean age ± standard deviation at enrollment was 6.9 ± 0.6 weeks. The anti-RV IgA titer was 4.01 ± 3.74 mg/ml pre-vaccination and substantially increased to 29.27 ± 80.64 mg/ml post-vaccination. The value of logIgA significantly increased (p = 0.003) from 0.28 ± 0.79 to 1.03 ± 0.54. The proportion of participants with equal to and greater than 3-fold and 4-fold shifts in pre- to post-vaccination antibody titer (IgA) were 55.4% and 48.3%, respectively. No adverse events or serious adverse events were recorded immediately within 30 min after the administration of each dose. The most common adverse events within 14 days after each visit were fever, unusual crying and irritability. Other adverse events occurred at a low rate, and no case of intussusception was noted.ConclusionsThe complete regimen of ROTAVAC® demonstrated an immunological response with clinically acceptable safety profile. Post-completion of this study, ROTAVAC® is now a WHO-prequalified vaccine and available in Vietnam. 相似文献